NCT00093990View on ClinicalTrials.gov

Tipifarnib Versus Best Supportive Care in the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML)

PHASE3CompletedINTERVENTIONAL
Enrollment

457

Participants

Timeline

Start Date

January 31, 2004

Study Completion Date

October 31, 2007

Conditions
Acute Myeloid Leukemia
Interventions
DRUG

Tipifarnib;Zarnestra; R115777

All Listed Sponsors
lead

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

INDUSTRY

NCT00093990 - Tipifarnib Versus Best Supportive Care in the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML) | Biotech Hunter | Biotech Hunter